文献速递眼底病与葡萄膜炎

经平坦部玻璃体切除术治疗葡萄膜炎

Pars Plana Vitrectomy for the Treatment of Uveitis.
PubMed 文献 · Am J Ophthalmol · 2018-03-28

本文系统综述了2005至2014年间34篇关于经平坦部玻璃体切除术(PPV)治疗葡萄膜炎的文献,其中32篇为回顾性病例系列,2篇为随机预试验。共纳入627例患者、708只眼,术后69%视力改善,黄斑囊样水肿比例由52%降至37%,口服糖皮质激素使用中位数由48%降至12%。作者认为尽管多数研究报道结局良好,但证据质量受限于标准化报告不足、研究设计局限及缺乏前瞻性数据。

要点

  • 34篇文献中32篇为回顾性病例系列,2篇为随机预试验,证据等级中位数SIGN为3、OCEBM为4。
  • 708只眼行PPV,术后视力改善356眼(69%)、不变95眼(18%)、变差68眼(13%)。
  • 黄斑囊样水肿由术前157/300眼(52%)降至术后112/300眼(37%)。

核心结论

  • 尽管几乎所有研究继续报道PPV治疗葡萄膜炎的结局良好,但数据质量仍受限于缺乏标准化报告结局、研究设计局限及前瞻性数据匮乏。

研究设计与样本

  • 系统文献综述,检索关于PPV治疗葡萄膜炎的相关文章,汇总并分析研究结果。
  • 最终纳入34篇文章,发表于2005年至2014年,其中32篇为回顾性病例系列,2篇为随机预试验。
  • 纳入627例患者、708只眼行PPV治疗葡萄膜炎,患者平均报告年龄43.4岁。

主要发现

  • PPV术前葡萄膜炎中位病程36.1个月(范围4-198个月),术后中位随访18.9个月(范围2-114个月)。
  • 519只眼报告视力,PPV术后视力改善356眼(69%)、不变95眼(18%)、变差68眼(13%)。
  • 术前300只眼中157眼(52%)记录有黄斑囊样水肿,术后300只眼中112眼(37%)记录有黄斑囊样水肿。
  • 报告的研究中,口服糖皮质激素使用中位数由术前48%改善至术后12%。
  • 报告的研究中,其他免疫抑制药物使用中位数由术前56%降至术后36%。

关键数值与推荐

  • 证据等级中位数:苏格兰校际指南网络(SIGN)为3,牛津循证医学中心(OCEBM)为4。
  • 不足50%的文章应用葡萄膜炎命名标准化(SUN)标准报告葡萄膜炎解剖位置。
  • 不足25%的研究应用SUN标准报告PPV前后前房细胞。
  • 不足10%的研究应用SUN标准对PPV前后前房闪辉进行分级。
  • 不足10%的研究应用标准化标准对PPV后玻璃体混浊进行分级。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 数据质量受限于缺乏标准化报告结局的应用。
  • 研究设计存在局限。
  • 前瞻性数据匮乏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To review and summarize evidence in the medical literature regarding the use of pars plana vitrectomy in the management of uveitis. DESIGN: Systematic literature review. METHODS: A systematic literature search was conducted for relevant articles on pars plana vitrectomy for the management of uveitis. Results from the studies were compiled and analyzed. RESULTS: Thirty-four articles, published from 2005 through 2014, were included in the final data analysis. Thirty-two manuscripts were from retrospective case series and 2 manuscripts were from randomized pilot studies. The median Scottish Intercollegiate Guidelines Network level of evidence grade was 3 and the median Oxford Center for Evidence-based Medicine level of evidence grade was 4. Fewer than 50% of the articles in the current study applied Standardization of Uveitis Nomenclature (SUN) criteria in regard to reporting the anatomic location of uveitis, fewer than 25% of studies applied SUN criteria in regard to the reporting of anterior chamber cells before and after PPV, fewer than 10% of studies applied SUN criteria to the grading of anterior chamber flare before and after PPV, and fewer than 10% of studies applied standardized criteria to the grading of vitreous haze after PPV. Overall, 627 patients and 708 total eyes undergoing PPV for uveitis were included. The average reported age of all patients was 43.4 years. The median duration of uveitis prior to PPV reported in the studies was 36.1 months (range 4-198 months). The median follow-up after PPV reported in the studies was 18.9 months (range 2-114 months). Vision was reported for 519 eyes and was improved in 356 eyes (69%), unchanged in 95 eyes (18%), and worse in 68 eyes (13%) following PPV. Preoperatively, 157 of 300 (52%) eyes in these studies had documented cystoid macular edema compared to 112 of 300 (37%) postoperatively. Median use of oral corticosteroids improved from 48% preoperatively to 12% postoperatively among the reporting studies. Median use of other immunosuppressive medications decreased from 56% preoperatively to 36% postoperatively among the reporting studies. CONCLUSIONS: Although nearly all studies continue to report favorable outcomes of PPV in the management of uveitis, the quality of data remains limited by a lack of application of standardized reporting outcomes, limitations in study design, and a paucity of prospective data.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Henry CR, Becker MD, Yang Y, et al. Pars Plana Vitrectomy for the Treatment of Uveitis. Am J Ophthalmol. 2018. PMID: 29601822. doi:10.1016/j.ajo.2018.03.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。